Dutasteride and Hair-Loss Genetics: What Testing Can Tell You

Both medicines act on the conversion of testosterone into DHT. Finasteride preferentially inhibits type 2 5-alpha-reductase. Dutasteride inhibits type 1 and type 2, encoded by SRD5A1 and SRD5A2. These are drug targets: proteins the medicine acts on. Dutasteride mechanism.

Genetic variation could matter at several points, including the drug's targets, hormone signaling, and drug clearance. These are different biological questions. A finding about how much medicine reaches the bloodstream does not, by itself, tell us how much hair a person will regrow.

In a randomized trial involving 917 men with androgenetic alopecia, researchers compared several dutasteride doses with finasteride and placebo over 24 weeks. Dutasteride 0.5 mg improved hair count and width more than finasteride 1 mg or placebo in that study. The trial supports a hair-growth effect, while its duration limits conclusions about longer-term outcomes. The doses here describe the study, not a personalized recommendation. Gubelin Harcha et al., 2014.

The trial did not establish a genetic rule for deciding who should take dutasteride instead of finasteride. A treatment can perform well on average while genetic prediction of individual benefit remains uncertain.

Off-label use means the U.S. approved indication does not include hair loss. It does not mean there is no clinical research on that use. Gene2Rx's current noncoverage concerns genetic interpretation; it is not a judgment that dutasteride is ineffective.

Different genetic questions in dutasteride research

Research area	What it investigates
SRD5A1 / SRD5A2	Variation in the enzyme targets and whether it affects inhibition or treatment response.
CYP3A4 / CYP3A5	Variation in enzymes involved in dutasteride metabolism and its relationship to drug exposure.
Other response candidates	Whether variants in genes such as DHRS9 and CYP26B1 correlate with changes in hair growth.

Functional studies of the target enzyme

Laboratory experiments have shown that SRD5A2 variants can change the enzyme's inhibition by dutasteride and finasteride. This is functional evidence that inherited differences could affect drug action. Translating those measurements into a person's expected hair growth requires clinical evidence as well. Makridakis and Reichardt, 2005.

A study of genetic differences in hair response

Researchers examined variants across 154 genes in 42 Korean men after six months of dutasteride treatment. They identified candidate associations, including variants in DHRS9 and CYP26B1. However, no individual variant remained statistically significant after correction for multiple testing, and there was no separate replication cohort. Rhie et al., 2019.

When many variants are tested, some can appear associated by chance. Correction for multiple testing helps account for that. These findings provide candidates for further study, rather than a confirmed set of responder and nonresponder genotypes.

Drug metabolism is another part of the story

A study of 79 healthy men receiving dutasteride with tamsulosin investigated genetic effects on drug exposure. Some CYP3A4/CYP3A5 findings for dutasteride appeared in initial analyses but did not remain significant after correction for multiple comparisons. The study did not measure hair regrowth. Its results therefore cannot be used as a dutasteride hair-response test or a genotype-based dosing rule. Villapalos-García et al., 2021.

More recent panel research

A 2025 retrospective study reported a dutasteride-response association involving SRD5A1 rs39848 within a 26-SNP panel. This is a relevant signal, but varied regimens and uncontrolled factors such as adherence limit interpretation. The authors acknowledged the need for prospective, controlled validation. Gaboardi et al., 2025; study limitations and author responses.

The research has not yet established a sufficiently supported variant-specific interpretation for Gene2Rx to report. The studies above contribute different kinds of evidence: enzyme experiments, exploratory hair-response associations, and measurements of drug exposure. They do not yet provide a reliable way to classify a new customer's expected benefit, side-effect risk, or dose.

Independent replication is especially important for the small hair-response study, whose individual variant findings did not survive multiple-testing correction. For metabolism findings, further work would need to connect a reproducible change in exposure to an outcome that matters for treatment. A variant associated with blood levels is not automatically a reason to change the dose.

Evidence that could support future coverage includes a clearly defined marker with reproducible effects, validation in additional patients, and a defensible explanation of what a positive or negative result means. Gene2Rx has not adopted a dutasteride guideline, and dutasteride is excluded from report medication totals.

Does a minoxidil result help choose dutasteride?

The Gene2Rx topical minoxidil guideline reports information about SULT1A1 rs1042028, a functional variant in an enzyme involved in activating minoxidil. That finding does not establish whether dutasteride will work better. Gene2Rx does not use it to recommend switching between hair-loss medicines.

A useful discussion includes the hair-loss diagnosis, previous response to treatment, expected benefit, side effects, and the reasons for considering an off-label medicine. Broader inhibition of DHT production does not settle which option best fits an individual.

Discuss sexual and breast-related adverse effects, pregnancy exposure precautions, and PSA interpretation. People who are pregnant or may be pregnant should not handle the capsules. Dutasteride is metabolized through CYP3A enzymes, so interacting medicines also matter; these medication interactions can be important even without a genetic test. Read the full safety and interaction information.

Compare the evidence on our finasteride and topical minoxidil pages, or visit the hair-loss medication overview.

• DailyMed: Avodart prescribing information. Approved use, mechanism, metabolism, and precautions.
• Gubelin Harcha et al. (2014): randomized comparison of dutasteride, finasteride, and placebo. A 24-week hair-growth trial in 917 men.
• Makridakis and Reichardt (2005): pharmacogenetic analysis of human steroid 5-alpha-reductase type II. Experimental effects of target-enzyme variation.
• Rhie et al. (2019): genetic variation associated with dutasteride response in androgenetic alopecia. Exploratory research in 42 Korean men.
• Villapalos-García et al. (2021): pharmacogenetics of dutasteride and tamsulosin. Drug-exposure research in healthy volunteers.
• Gaboardi et al. (2025): 26-SNP panel study of androgenetic alopecia therapy. Retrospective treatment-response research; see also the authors' discussion of its limitations.